ClinicalTrials.gg

Program

NVG-291

A development code.

Its studies are mostly in Spinal Cord Injuries · Quadriplegia, led by NervGen Pharma.

Furthest: phase 3, since Aug 18, 20263 company-led studies, 1 open or runningNext primary completion: Jul 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
NervGen Pharma31 open or runningphase 3since Aug 18, 2026Mar 15, 2022Jul 2027phase 3 · NCT07799532

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 15, 2022First study: phase 1 study in Spinal Cord InjuriesFirst studyNCT05308953 · 74 enrolled · Australia
  2. Jul 16, 2023Phase 2 study in Spinal Cord InjuriesNCT05965700 · 24 enrolled · United States
  3. Aug 18, 2026Phase 3 study in QuadriplegiaPhase 3 reachedNCT07799532 · 150 planned · United States, Canada

Ahead

  1. Jul 2027Primary completion: phase 3 study in QuadriplegiaNCT07799532

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07799532Quadriplegia · United States, Canada3RecruitingJul 2027150
NCT05965700Spinal Cord Injuries · United States2CompletedDec 31, 202524
NCT05308953Spinal Cord Injuries · Australia1CompletedJun 4, 202374

How it is read

Names in the registry

  • “NVG-291”, 3 entries

Codes read as this program: NVG291.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.